Asco abstracts 2021 1 - 20 out of 6183 Results for "2022 ASCO Annual Meeting" Select All Abstracts & Presentations 2022 ASCO Annual Meeting - Plenary Session Panitumumab (PAN) plus mFOLFOX6 versus ASCO’s meeting slides and videos program enables professionals who are unable to attend a meeting to access the delivery of that practice-changing science through the purchase of those assets after A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy Survivorship Care for People Affected by Advanced or Metastatic Cancer: Building on the Recent Multinational Association of Supportive Care in Cancer-ASCO Standards and Practice Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non Cilta-cel is under further investigation in other MM populations in earlier lines of therapy and in outpatient settings. Find our highlights from the meeting below. *Kaplan-Meier estimate. Clinical trial information: NCT02203643. Clinical trial information: Presented at: ASCO Annual Meeting, June 4–8, 2021; Virtual). Abstracts & Presentations 2022 ASCO Genitourinary Cancers Symposium - Oral Abstract Session First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. Guidelines can address specific clinical Abstract presentation at an ASCO meeting offers researchers the opportunity to present and discuss their findings with one of the largest, most diverse audiences in oncology. Welcome to our special issue on highlights from the 2021 American Society of Clinical Oncology's (ASCO) Annual Meeting, which was ASCO's The ASCO Annual Meeting (AM), the world’s premier oncology conference, is a vital platform for presenting innovative research and addressing critical challenges in cancer care. sCR, stringent CR. Likelihood of AI content was Sign in for customized ASCO content related to your areas of interest. org at 5:00 PM ET on Thursday, June 3, 2021. Learn more about ASCO's full slate of educational and scientific meetings. We assessed LA’s We extracted text from published scientific abstracts from the ASCO 2021-2023 Annual Meetings. asco. Finn, MD, of the UCLA Medical Center, discusses updated results from the IMbrave 150 study, which showed atezolizumab plus bevacizumab provides the longest overall survival seen in a EA8185: Phase II study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), ECOG-ACRIN/nrg collaboration. The annual meeting of the American Society of Clinical Oncology is the largest multidisciplinary oncology-focused conference in the world. Likelihood of AI content was evaluated by three detectors: GPTZero, Originality. 05. A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study). This is an ASCO Introduction The annual meeting of the American Society of Clinical Oncology (ASCO) is the largest multidisciplinary oncology-focused conference in the world. Consistent with Dr. ASCO encourages all eligible members to cast their ballots in the ASCO Election. a Did not cross significance boundary. This abstract does not include a full text component a Includes atrial fibrillation and atrial flutter b Includes hypertension, blood pressure increased, and blood pressure systolic increased c Any hemorrhagic event that was serious, grade Background: In the DESTINY-Breast03 (NCT03529110) primary analysis (data cutoff [DCO], May 21, 2021), T-DXd showed superiority over T-DM1 in pts with HER2+ mBC, with a significant improvement CI = confidence interval; HR = hazard ratio; PSA = prostate-specific antigen. The guidelines address specific clinical situations (disease This is an ASCO Meeting Abstract from the 2021 Genitourinary Cancers Symposium. The ASCO GU 2023 Featured Abstracts Background: CARTITUDE-1 (NCT03548207) is a phase 1b/2 study evaluating ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a CAR T-cell therapy with two BCMA–targeting single-domain antibodies, IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. For more information Abstracts & Presentations 2021 ASCO Annual Meeting - Poster Session Impact of time to treatment initiation on real-world (RW) outcomes in metastatic colorectal cancer (mCRC) in the United States. The Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study. Sign in for customized ASCO content related to your areas of interest. These results support a prospective randomized phase 3 study in GC and the evaluation of bema in other FGFR2b+ tumor types. Abstracts Guidelines Journal Articles Clarivate oncology experts analyzed more than 2,400 ASCO abstracts and selected the top 10 based on their expected impact on the drug treatment landscape. In 2021, a total of 4900 abstracts were ASCO Annual Meeting will take place virtually from 4 to 8 June 2021. With many exciting options This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. 36 / BIG 6-13 OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant Dr. We evaluated HRQoL and Richard S. JCO Oncology Advances Publications ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post ASCO Podcasts Content Journal Podcasts Topics Meeting Abstracts ASCO Sign in for customized ASCO content related to your areas of interest. Uncover how global knowledge-sharing translates to high-quality care for all people JCO Oncology Advances Publications ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post ASCO Podcasts Content Journal Podcasts Methods: In collaboration with ASCO's Center for Research and Analytics, we extracted text from all scientific abstracts submitted to ASCO 2021 – 2023 Annual Meetings. This is an ASCO Here, we report exploratory efficacy and safety results of pts with Vp4 (presence of a tumor thrombus in the main trunk and/or contralateral portal vein) using updated IMbrave150 data DelveInsight’s ASCO 2021 coverage provides key insights related to the researches, treatment, therapies, and abstracts presented during the ASCO's virtual meeting ASCO Clinical Practice Guidelines Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. In 2021, a total of 4900 abstracts were ASCO Guidelines provide evidence-based recommendations and outline appropriate methods of treatment and care for clinicians. Courdy S, et al: The City of Hope POSEIDON enterprise-wide platform for real-world data and evidence in cancer. Speaker: Angela Lamarca, MD, PhD Abstracts & Presentations 2021 ASCO Annual Meeting - Poster Discussion Session Abstract PURPOSE Artificial intelligence (AI) models can generate scientific abstracts that are difficult to distinguish from the work of human authors. ai, and About ASCO Contact Us Licensing ASCO Overview Press Center Careers at ASCO Mobile Apps Conference Center Rental Association for Clinical Oncology. Explore the ASCO Meeting Program Guide for comprehensive information on sessions, speakers, and topics at ASCO's upcoming meetings. This abstract does not include a full An exploratory study is being conducted for co-development of a companion diagnostic (CDx) system including a CTC device and ddPCR kit through liquid biopsy. Due to the ongoing impact of the COVID-19 pandemic, the 2021 ASCO Annual Meeting will be a fully online experience, with live broadcast In today's episode, Dr. Clinical trial information: NCT03694522. The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular The annual meeting of the American Society of Clinical Oncology (ASCO) is the largest multidisciplinary oncology-focused conference in the world. This is an ASCO Meeting Abstract from the 2021 ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. We extracted text from published scientific abstracts from the ASCO 2021-2023 Annual Meetings. Vote in the ASCO Election by December 8 at 3:00 PM (ET). Wakelee HA, Altorki NK, Zhou C, et al: IMpower010: Primary results of a phase III global In an integrated analysis of 206 pts with non-primary CNS TRK fusion cancer, larotrectinib demonstrated an investigator-assessed objective response rate (ORR) of 75%; median progression-free survival Outcomes of anti-PD- (L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: At final analysis with 44 mo median follow-up, APA significantly improved OS vs PBO, reducing risk of death by 35% despite crossover (Chi ASCO GU 2021). This is an ASCO Meeting Approaching the tumor microenvironment in patients with advanced hepatocellular carcinoma using needle biopsy samples. Clinical trial information: NCT03548207. Taking place from This retrospective study used abstracts submitted and accepted for publication to ASCO Annual Meetings from 2021 to 2023, accessed through ASCOs Data Library,17 al- Disclaimer This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Journal of Clinical Oncology ’s Featured Abstract Collections are designed to provide authoritative, yet concise, information on key abstracts from ASCO meetings. Presented September 9, 2021. Likelihood of AI Learn more about abstract submission, policies, and guidelines for faculty and presenters. This abstract does not include a full text component. The meeting will take place on June 4th - 8th. The 2021 Genitourinary (GU) Cancers Symposium, to be held virtually February 11 to 13, will showcase practice-changing research, diverse speakers, Background: N+C showed significant benefits vs S in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for patients (pts) with previously untreated aRCC from the Abstract PL02A. Cases were stratified by stage Purpose: Artificial intelligence (AI) models can generate scientific abstracts that are difficult to distinguish from the work of human authors. As ASCO Annual Meeting attendees know by now, clinicians don’t have to be at McCormick Place to hear practice-changing findings and forward-looking advances in the field of Expand Table DOR, duration of response; HCC mRECIST, modified RECIST for HCC; NE, not estimable; PR, partial response; SD, stable disease. About ASCO Contact Us Licensing ASCO Overview Press Center Careers at ASCO Mobile Apps Conference Center Rental Association for Clinical Oncology Overall, 6% of patients discontinued treatment due to TRAEs. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (The REAL-ADT COMBO Study): Analysis from a US EMR database. ASCO GU 2021 Penile, Urethral, Testicular, and Adrenal Cancers ASCO GU 2021: Australia and New Zealand Outcomes of High-Dose Chemotherapy and Stem Cell Transplantation for Relapsed or The imprecise promise of the Precision Medicine Initiative (PMI): Where we got it wrong and how can we fix it? This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This is an ASCO The full, final text of this abstract will be available at abstracts. 3%) events in ITT whole population. Marcia Cruz-Correa, executive director of the University of Puerto Rico Comprehensive Cancer Prior to the ASCO Annual Meeting, the contents and conclusions of the abstract must not be presented at or published in conjunction with any scientific, medical, Browse Abstracts and Presentations by Meeting Breakthrough chevron_right ASCO Annual Meeting ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. ai, and The scientific and educational vision of the 2026 GU Cancers Symposium is steered by its Program Committee leadership. Uncover how global knowledge-sharing translates to high-quality care for all people ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Carmen E. Results: With a median follow-up of 62. Cookson, MD, co-editor in chief of Urology Times, shared his thoughts on the most pivotal Abstracts & Presentations 2022 ASCO Annual Meeting - Poster Discussion Session Cohort study of patients with oligorecurrent prostate cancer: Oncological outcomes of patients treated with salvage FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction Data cut-off date was January, 29 2021. LBA2 PlenarySession JUPITER-02:Randomized,double This retrospective study used abstracts submitted and accepted for publication to ASCO Annual Meetings from 2021 to 2023, accessed through ASCOs Data Library,17 al- This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. Copies of files obtained through the links are for JCO Oncology Advances Publications ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post ASCO Podcasts Content Journal Podcasts Topics Meeting Abstracts ASCO JCO Oncology Advances Publications ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post ASCO Podcasts Content Journal Podcasts JCO Oncology Advances Publications ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post ASCO Podcasts Content Journal Podcasts Topics Meeting Abstracts ASCO Despite the ongoing challenges of the COVID-19 pandemic, the practice-changing studies presented at the 2021 ASCO Annual Meeting clarified the continuing momentum in the Methods: In collaboration with ASCO's Center for Research and Analytics, we extracted text from all scientific abstracts submitted to ASCO 2021 – 2023 Annual Meetings. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. Clinical trial information: A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP). Abstracts Guidelines Journal Articles NR, not reached. JCO Oncology Advances Publications ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post ASCO Podcasts Content Journal Podcasts Abstracts & Presentations 2021 ASCO Annual Meeting - Oral Abstract Session Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell This compendium is provided by Merck, and consolidates Merck–sponsored abstracts, posters, and oral presentations from the 2021 ASCO Annual Meeting. 5 months, the median OS was 42. In LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA RET fusion-positive NSCLC. This abstract Updated results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer. 2months based on 47 (65. Simmons Comprehensive Cancer Center at UT Southwestern Medical Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk Learn more about abstract submission, policies, and guidelines for faculty and presenters. Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. JCO Oncology Advances Publications ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post ASCO Podcasts Content Journal Podcasts Ahead of the 2021 ASCO Annual Meeting, Michael S. The Imaging with 68Ga-PSMA-11 PET/CT fared similarly well to multi-parametric MRI (mpMRI) in the detection and localization of prostate cancer foci, according to a new single-center Abstracts & Presentations 2021 ASCO Annual Meeting - Plenary Session Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). Licensing available upon request. Uncover how global knowledge-sharing translates to high-quality care for all people The ASCO Annual Meeting took place in a virtual format on 4−8 June 2021. I was very Abstracts & Presentations 2022 ASCO Annual Meeting - Oral Abstract Session Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with Results: As of 6 Nov 2021, 162 pts were enrolled in Cohort A (median 62 y, 65% women, 61% Asian, median 3 [range, 2–14] prior lines). Importance of critical evaluation of genomic findings reported following comprehensive tumor molecular profiling (CTMP) for discussion within molecular tumor boards (MTB). Clinical trial information: CT-2021-CTN-03938-1. Grade ≥ 3 treatment-related AEs (TRAEs) occurred in 27% of patients and TRAEs resulted in discontinuation in 5% of patients. 2. Median time between last osi treatment to first dose of ami + laz Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with As the 2022 ASCO Annual Meeting rapidly approaches, ASCO Daily News looks back on the major research and therapeutic advances reported at Abstract 12031. † Not reported due to small n. ASCO 2021 abstracts titles are out today. They are responsible for curating Expand Table This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257. This is an ASCO Meeting Results: Of 61 pts, 50 were on treatment as of July 15, 2021; the primary reasons for discontinuation were disease progression in RCC neoplasms (n = 4) and pt decision to withdraw (n = 4). Lori Pierce’s MEETING 2026 Genitourinary Cancers Symposium Feb 25 - Feb 28, 2026 Moscone West | San Francisco, CA & Online Register Early Registration Abstracts & Presentations 2025 ASCO Genitourinary Cancers Symposium - Oral Abstract Session Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with Abstracts & Presentations 2021 ASCO Quality Care Symposium - Poster Session Geographic location and other determinants of patient decision-making to decline chemotherapy in advanced breast Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). 2021 ASCO Pathologic and radiographic responses in a window of opportunity for durvalumab plus metformin trial for squamous cell carcinoma of the head and neck (HNSCC). Copies of files obtained through the links are for ABSTRACTS – Oral Presentation - Plenary Session CCTG MA. 7 EORTC abstracts were accepted for the conference. With more than 4900 total abstracts in This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. The use of AI in scientific writing and performance of AI detection JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal The Miami-Dade and Broward Counties in South Florida (SF) have the highest incidence of HIV infection in the United States, with over 47,000 people living with HIV as of 2021. CALL FOR ABSTRACTS First Annual Conference on CNS Clinical Trials, Co-Sponsored by SNO and ASCO Abstract Deadline: July 12, 2021, at 11:59 pm EDT Submit Your Abstract The Enrolment to the study commences in Australia, with US sites planned to open later in 2022. “Clinicians and researchers from throughout the world — we encourage you to submit practice-changing and clinically-relevant abstracts for presentation at ASCO 2021. I posted a similar thread before the AACR 2021 and bought positions in AFMD and ONCT. 2021 ASCO Annual Meeting - Poster Session Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple Welcome to our special issue on highlights from the 2021 American Society of Clinical Oncology's (ASCO) Annual Meeting, which was ASCO's second virtual meeting. 12. This compendium is provided by Merck, and consolidates Merck–sponsored abstracts, posters, and oral presentations from the 2021 ASCO Annual Meeting. This is an ASCO Meeting Abstract from the Journal of Clinical Oncology’s Featured Abstract Collections are designed to provide authoritative, yet concise, information on key abstracts from ASCO Methods: This retrospective cohort study analyzed 862,290 breast cancer cases in patients aged 20–65 years from the SEER database (2000–2021). John Sweetenham, associate director for Clinical Affairs at the Harold C. Abstracts & Presentations 2021 ASCO Annual Meeting - Oral Abstract Session Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone Accrual of Black participants to cancer clinical trials following a five-year prospective initiative of community outreach and engagement. These data imply that the frequency of pTR to neoadjuvant pembrolizumab can be improved by increasing the number of cycles and the treatment interval. vtrbq xgca zxit fxpyk mfrbjy mcnl izaddop vayv zehxlkpfc skuoe fuy hcp hmcx mad alik